Santhera publiziert Zeitplan für die Aktienzusammenlegung NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO...
Shareholders Approve all Board Proposals at Today’s Annual General Meeting Pratteln, Switzerland, June 27, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders approved...
Santhera vergibt exklusive Nordamerika-Lizenz für Vamorolone an Catalyst Pharmaceuticals in einer Transaktion im Wert von bis zu USD 231 Millionen zuzüglich Lizenzgebühren Ad-hoc-Mitteilung...
Santhera Publishes Agenda for its Annual General Meeting NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO...
Santhera veröffentlicht Jahresbericht 2022 Ad-hoc-Mitteilung gemäss Art. 53 KR Pratteln, Schweiz, 31. Mai 2023 – Santhera Pharmaceuticals (SIX: SANN) gibt die Veröffentlichung des...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 190.2 | 190.2 | 190.2 | 2218 | 190.2 | DE |
4 | 0 | 0 | 190.2 | 190.2 | 190.2 | 1535 | 190.2 | DE |
12 | 0 | 0 | 190.2 | 190.2 | 190.2 | 852 | 190.2 | DE |
26 | 0 | 0 | 190.2 | 190.2 | 190.2 | 499 | 190.2 | DE |
52 | 0 | 0 | 190.2 | 190.2 | 190.2 | 451 | 190.2 | DE |
156 | 0 | 0 | 190.2 | 190.2 | 190.2 | 1867 | 190.2 | DE |
260 | 0 | 0 | 190.2 | 190.2 | 190.2 | 1753 | 190.2 | DE |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約